Ardsley Advisory Partners’s Alder Biopharmaceuticals ALDR Stock Holding History

Ardsley Advisory Partners’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-20,000	Closed	-$235K	–	193
2019 Q2	$235K	Sell	20,000 -10,000	-33%	-$121K	0.04%	127
2019 Q1	$410K	Buy	+30,000	New	+$389K	0.08%	92
2017 Q4	–	Sell	-30,000	Closed	-$368K	–	185
2017 Q3	$368K	Buy	+30,000	New	+$313K	0.05%	105
2017 Q2	–	Sell	-10,000	Closed	-$208K	–	201
2017 Q1	$208K	Buy	+10,000	New	+$221K	0.03%	136

Other funds holding ALDR

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ardsley Advisory Partners's ALDR Position: Q3 2019 in Review

Ardsley Advisory Partners sold out of Alder Biopharmaceuticals (ALDR) in Q3 2019, closing a stake of 20,000 shares — an estimated $235K sold.

Ardsley Advisory Partners first reported a position in ALDR in Q1 2017 and held it in 4 quarters. The position peaked at $410K in Q1 2019. 143 funds tracked by Wall St. Rank hold ALDR as of Q3 2019.

Ardsley Advisory Partners reported no remaining Alder Biopharmaceuticals position as of Q3 2019 after selling out during the quarter.
Ardsley Advisory Partners sold 20,000 Alder Biopharmaceuticals shares in Q3 2019, an estimated $235K.
Ardsley Advisory Partners first reported a position in Alder Biopharmaceuticals in Q1 2017 and held it in 4 quarters.
Ardsley Advisory Partners's Alder Biopharmaceuticals position peaked at $410K in Q1 2019.
143 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2019.

Based on Ardsley Advisory Partners's 13F filing for Q3 2019, filed 14 Nov 2019.